BACKGROUND: An increased number of podocyte-derived extracellular vesicles (pEVs) may reflect podocyte injury in renal disease. Elevated glomerular pressure and other insults may injure podocytes, yet it remains unclear whether the numbers of pEVs are altered in hypertensive patients. We tested the hypothesis that urinary pEV levels would be elevated in patients with renovascular hypertension (RVH) compared with essential hypertension (EH) or healthy volunteers (HVs). METHODS: We prospectively enrolled patients with EH ( n = 30) or RVH ( n = 31) to study renal blood flow (RBF) and cortical perfusion using multidetector computed tomography under controlled condition (regulated sodium intake and renin-angiotensin blockade). After isolation from urine samples, pEVs (nephrin and podocalyxin positive) were characterized by flow cytometry. Fourteen RVH patients were studied again 3 months after stenting or continued medical therapy. HVs ( n = 15) served as controls. RESULTS: The fraction of pEV among urinary EVs was elevated in RVH compared with HVs and EH (11.4 ± 6.4, 6.8 ± 3.4 and 6.3 ± 3.7%, respectively; P < 0.001) and remained unchanged after 3 additional months of therapy and after controlling for clinical parameters. However, eGFR- and age-adjusted pEV levels did not correlate with any clinical or renal parameters. CONCLUSIONS: In hypertensive patients under controlled conditions, urinary pEV levels are elevated in patients with RVH and low eGFR compared with patients with EH and relatively preserved renal function. These pEVs may reflect podocyte injury secondary to kidney damage, and their levels might represent a novel therapeutic target.
BACKGROUND: An increased number of podocyte-derived extracellular vesicles (pEVs) may reflect podocyte injury in renal disease. Elevated glomerular pressure and other insults may injure podocytes, yet it remains unclear whether the numbers of pEVs are altered in hypertensive patients. We tested the hypothesis that urinary pEV levels would be elevated in patients with renovascular hypertension (RVH) compared with essential hypertension (EH) or healthy volunteers (HVs). METHODS: We prospectively enrolled patients with EH ( n = 30) or RVH ( n = 31) to study renal blood flow (RBF) and cortical perfusion using multidetector computed tomography under controlled condition (regulated sodium intake and renin-angiotensin blockade). After isolation from urine samples, pEVs (nephrin and podocalyxin positive) were characterized by flow cytometry. Fourteen RVH patients were studied again 3 months after stenting or continued medical therapy. HVs ( n = 15) served as controls. RESULTS: The fraction of pEV among urinary EVs was elevated in RVH compared with HVs and EH (11.4 ± 6.4, 6.8 ± 3.4 and 6.3 ± 3.7%, respectively; P < 0.001) and remained unchanged after 3 additional months of therapy and after controlling for clinical parameters. However, eGFR- and age-adjusted pEV levels did not correlate with any clinical or renal parameters. CONCLUSIONS: In hypertensive patients under controlled conditions, urinary pEV levels are elevated in patients with RVH and low eGFR compared with patients with EH and relatively preserved renal function. These pEVs may reflect podocyte injury secondary to kidney damage, and their levels might represent a novel therapeutic target.
Authors: Elena Daghini; Andrew N Primak; Alejandro R Chade; James D Krier; Xiang-Yang Zhu; Erik L Ritman; Cynthia H McCollough; Lilach O Lerman Journal: Radiology Date: 2007-05 Impact factor: 11.105
Authors: Mu Li; Alex J Rai; G Joel DeCastro; Emily Zeringer; Timothy Barta; Susan Magdaleno; Robert Setterquist; Alexander V Vlassov Journal: Methods Date: 2015-03-24 Impact factor: 3.608
Authors: Iasmina M Craici; Steven J Wagner; Kent R Bailey; Patrick D Fitz-Gibbon; Christina M Wood-Wentz; Stephen T Turner; Suzanne R Hayman; Wendy M White; Brian C Brost; Carl H Rose; Joseph P Grande; Vesna D Garovic Journal: Hypertension Date: 2013-03-25 Impact factor: 10.190
Authors: Ahmed Saad; Sandra M S Herrmann; John Crane; James F Glockner; Michael A McKusick; Sanjay Misra; Alfonso Eirin; Behzad Ebrahimi; Lilach O Lerman; Stephen C Textor Journal: Circ Cardiovasc Interv Date: 2013-07-30 Impact factor: 6.546
Authors: Kenneth W Witwer; Edit I Buzás; Lynne T Bemis; Adriana Bora; Cecilia Lässer; Jan Lötvall; Esther N Nolte-'t Hoen; Melissa G Piper; Sarada Sivaraman; Johan Skog; Clotilde Théry; Marca H Wauben; Fred Hochberg Journal: J Extracell Vesicles Date: 2013-05-27
Authors: Li-Hong Zhang; Xiang-Yang Zhu; Alfonso Eirin; Arash Aghajani Nargesi; John R Woollard; Adrian Santelli; In O Sun; Stephen C Textor; Lilach O Lerman Journal: Am J Physiol Renal Physiol Date: 2019-05-01
Authors: In O Sun; Adrian Santelli; Abdelrhman Abumoawad; Alfonso Eirin; Christopher M Ferguson; John R Woollard; Amir Lerman; Stephen C Textor; Amrutesh S Puranik; Lilach O Lerman Journal: Hypertension Date: 2018-11 Impact factor: 10.190
Authors: Uta Erdbrügger; Charles J Blijdorp; Irene V Bijnsdorp; Francesc E Borràs; Dylan Burger; Benedetta Bussolati; James Brian Byrd; Aled Clayton; James W Dear; Juan M Falcón-Pérez; Cristina Grange; Andrew F Hill; Harry Holthöfer; Ewout J Hoorn; Guido Jenster; Connie R Jimenez; Kerstin Junker; John Klein; Mark A Knepper; Erik H Koritzinsky; James M Luther; Metka Lenassi; Janne Leivo; Inge Mertens; Luca Musante; Eline Oeyen; Maija Puhka; Martin E van Royen; Catherine Sánchez; Carolina Soekmadji; Visith Thongboonkerd; Volkert van Steijn; Gerald Verhaegh; Jason P Webber; Kenneth Witwer; Peter S T Yuen; Lei Zheng; Alicia Llorente; Elena S Martens-Uzunova Journal: J Extracell Vesicles Date: 2021-05-21
Authors: Seo Rin Kim; Xiangyu Zou; Hui Tang; Amrutesh S Puranik; Abdelrhman M Abumoawad; Xiang-Yang Zhu; LaTonya J Hickson; Tamara Tchkonia; Stephen C Textor; James L Kirkland; Lilach O Lerman Journal: J Cell Physiol Date: 2020-07-13 Impact factor: 6.384